Want to see FMS full AI Analyst Report?
FMS Stock Chart & Stats
$24.59
$0.28(1.14%)
At close: 4:00 PM EDT
$24.59
$0.28(1.14%)
Day’s Range― - ―
52-Week Range$20.02 - $27.64
Previous Close$24.87
Volume453.25K
Average Volume (3M)565.69K
Market Cap
$13.62B
Enterprise Value$24.57K
Total Cash (Recent Filing)$1.45B
Total Debt (Recent Filing)$10.96B
Price to Earnings (P/E)13.6
Beta0.52
Next Earnings
Nov 03, 2026EPS Estimate
0.62Next Dividend Ex-DateN/A
Dividend Yield3.37%
Share Statistics
EPS (TTM)1.67
Shares Outstanding537,129,300
10 Day Avg. Volume542,998
30 Day Avg. Volume565,692
Financial Highlights & Ratios
PEG Ratio0.14
Price to Book (P/B)0.83
Price to Sales (P/S)0.60
P/FCF Ratio6.96
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda<0.01
Forecast
1Y Price Target
$23.57Price Target Upside-4.16% Downside
Rating ConsensusModerate Sell
Number of Analyst Covering3
EPS Forecast (FY)2.33
Revenue Forecast (FY)$22.36B
Bulls Say, Bears Say
Bulls Say
Cash GenerationSustained high operating cash flow and sizable free cash flow (FCF ≈63% of net income) provide durable internal funding for capex, clinical rollout, buybacks and debt service. This strengthens capital allocation optionality and cushions the business versus reimbursement or volume variability over the next several quarters.
Profitability And Cost TransformationMeaningful margin expansion and recurring FME25+ savings indicate structural cost improvement and better operating leverage. Sustained efficiency gains can support margins even with modest revenue growth, improving long‑term cash conversion and resilience to inflationary or reimbursement pressures.
Clinical/technology LeadershipBroad adoption of the 5008X CAREsystem and programs like BEACON-US create durable competitive advantages: stronger clinical outcomes, differentiated product platform and recurring consumables demand. Technology-led clinical differentiation supports sticky customer relationships and long-term consumables revenue.
Bears Say
U.S. Treatment VolumesA persistent execution shortfall in U.S. referral capture constrains the core recurring service revenue stream in the largest market. If referral conversion and clinic throughput don't improve, it could permanently slow organic growth and reduce leverage on fixed clinic economics over coming quarters.
China/regulatory HeadwindsRegulatory tightening and tender pressure in China introduce structural revenue and margin risk in a key product market. Strategic review and leadership changes indicate material uncertainty; prolonged softness or stricter procurement rules could erode product sales and margin contribution long term.
Balance Sheet FlexibilityWhile leverage has improved versus earlier peaks, debt remains material and equity has declined, reducing headroom for large strategic investments or shocks. Moderate leverage limits optionality for M&A or prolonged buybacks if cash generation or profitability deteriorates.
Fresenius Medical Care News
FMS FAQ
What was Fresenius Medical Care Corp.’s price range in the past 12 months?
Fresenius Medical Care Corp. lowest stock price was $20.02 and its highest was $27.64 in the past 12 months.
What is Fresenius Medical Care Corp.’s market cap?
Fresenius Medical Care Corp.’s market cap is $13.62B.
When is Fresenius Medical Care Corp.’s upcoming earnings report date?
Fresenius Medical Care Corp.’s upcoming earnings report date is Nov 03, 2026 which is in 85 days.
How were Fresenius Medical Care Corp.’s earnings last quarter?
Fresenius Medical Care Corp. released its earnings results on Aug 03, 2026. The company reported $0.647 earnings per share for the quarter, beating the consensus estimate of $0.616 by $0.031.
Is Fresenius Medical Care Corp. overvalued?
According to Wall Street analysts Fresenius Medical Care Corp.’s price is currently Overvalued.
Does Fresenius Medical Care Corp. pay dividends?
Fresenius Medical Care Corp. pays a Annually dividend of $0.864 which represents an annual dividend yield of 3.37%. See more information on Fresenius Medical Care Corp. dividends here
What is Fresenius Medical Care Corp.’s EPS estimate?
Fresenius Medical Care Corp.’s EPS estimate is 0.62.
How many shares outstanding does Fresenius Medical Care Corp. have?
Fresenius Medical Care Corp. has 537,129,300 shares outstanding.
What happened to Fresenius Medical Care Corp.’s price movement after its last earnings report?
Fresenius Medical Care Corp. reported an EPS of $0.647 in its last earnings report, beating expectations of $0.616. Following the earnings report the stock price went down -1.559%.
Which hedge fund is a major shareholder of Fresenius Medical Care Corp.?
Currently, no hedge funds are holding shares in FMS
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Fresenius Medical Care Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Sell
Average Price Target:
$23.57 (-4.16% Downside)
$23.57 (-4.16% Downside)
Blogger Sentiment
Bullish
FMS Sentiment 83%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Increased
By 1.9M Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▼ 8.1%
Last 30 Days ▼ 10.5%
Last 30 Days ▼ 10.5%
News Sentiment
Very Bearish
Bullish news 8%
Bearish news 92%
Bearish news 92%
Technicals
SMA
Positive
20 days / 200 days
Momentum
-5.53%
12-Months-Change
Fundamentals
Return on Equity
3.37%
Trailing 12-Months
Asset Growth
2.54%
Trailing 12-Months
Company Description
Fresenius Medical Care Corp.
Fresenius Medical Care AG & Co. KGaA specializes in comprehensive kidney dialysis treatment and associated services, operating across Germany, North America, and numerous international territories. Through an extensive network of outpatient clinics, it delivers essential dialysis therapy along with laboratory and diagnostic support. For home-based care, the company supplies necessary equipment, provides comprehensive training, and offers ongoing patient assistance, including clinical oversight and coordinating supply deliveries directly to patients. In the United States, Fresenius Medical Care also contracts with hospitals to provide vital dialysis interventions for hospitalized individuals suffering from end-stage renal disease (ESRD) and acute kidney failure. Beyond services, it is a prominent developer, manufacturer, and distributor of a broad range of dialysis products. This portfolio encompasses polysulfone dialyzers, hemodialysis machines, peritoneal dialysis cyclers and solutions, concentrates, bloodlines, renal pharmaceuticals, and water treatment systems. Additionally, the company produces non-dialysis medical devices, including acute cardiopulmonary and apheresis products. Its pharmaceutical division focuses on developing, acquiring, and in-licensing specialized renal medications, distributing these essential drugs and supplies to both individual patients' homes and dialysis centers. The company also extends its medical offerings to include a variety of specialized services such as vascular, cardiovascular, and endovascular care, operating ambulatory surgery centers for vascular procedures, and providing physician services in nephrology and cardiology. Products are sold directly to dialysis clinics, hospitals, and specialized treatment centers, complemented by sales through local teams, independent distributors, dealers, and agents. By February 23, 2022, Fresenius Medical Care managed an impressive network of 4,171 outpatient dialysis clinics across roughly 150 countries. Established in 1996, the company maintains its headquarters in Bad Homburg, Germany.
FMS Company Deck
FMS Earnings Call
Q2 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call balanced meaningful operational and financial progress against notable execution and external headwinds. Highlights include strong operating income growth (+23%), margin expansion (+180 bps), EUR 67 million of sustainable FME25+ savings, improved cash generation (+11% operating cash flow), a successful 5008X rollout (227 clinics, >600k treatments) and a profitable turnaround in value-based care (EUR 18m operating income). Lowlights include a U.S. referral/capture execution gap driving a 0.9% decline in U.S. same‑market treatments and an expectation that U.S. volumes will remain around the Q2 level for 2026, regulatory and inflationary pressures in China and Care Enablement (EUR ~20m Q2 headwind), a EUR 103m special-item charge (TAVNEOS impairment), and TDAPA timing creating an H2 earnings headwind (net ~EUR 50m for the year). Overall, the positives around profitability, cash flow, capital returns and product rollout outweigh the near-term volume and regulatory challenges, though execution on U.S. referrals and China strategy will be key to sustaining momentum.View all FMS earnings summariesFMS Stock 12 Month Forecast
Average Price Target
$23.57
▼(-4.16% Downside)
Technical Analysis
Ownership Overview
―
Insiders
3.23% Mutual Funds
3.27% Other Institutional Investors
93.47% Public Companies and
Individual Investors